Working on the streets in medically underserved Philadelphia neighborhoods, members of the Do One Thing program have been able to identify residents chronically infected with hepatitis C and help them overcome the hurdles that prevent people from being cured, according to a new study in the Journal of General Internal Medicine.
16 February 2015 | Eurekalert Inf Dis
In 2 recent studies, statins and aspirin have been associated with lower rates of progression of liver fibrosis in patients with hepatitis C. Strategies for slowing the rate of progression of liver fibrosis are important for these reasons: (1) the high cost of treatment for hepatitis C; and (2) updated guidelines that recommend prioritizing treatment to sicker patients and postponing treatment in other groups.
11 February 2015 | HCP Live
Diagnosis and screening currently too complex and expensive, but new options emerging.
20 January 2015 | UNITAID press release
NICE is consulting on draft guidance on a device that aims to diagnose and monitor liver damage, without the need for surgery. The provisional recommendations support using the device, Virtual Touch Quantification (VTq), in adults and children with chronic hepatitis B or C who need assessment of liver fibrosis.
15 January 2015 | NICE
Doctors should resist the urge to screen a wider group of patients for hepatitis C, a group of physicians said today in the British Medical Journal, despite the introduction of new drugs that can cure the liver disease. Expanded screening would flag the disease in people who are unlikely to die from it, leading to unnecessary treatment that may itself be harmful, said the group, including Kenneth Lin, an associate professor at Georgetown University School of Medicine.
14 January 2015 | Bloomberg
“Hepatitis C infection has serious long-term side effects, such as damage to the liver, but our research indicates that it does not affect the brain,” said lead author David Clifford, MD, of Washington University.
15 December 2014 | Washington University press release
A new toolkit on screening for chronic viral hepatitis seeks to raise awareness, improve knowledge and motivate public health professionals in Europe to take action. Knowledge and understanding of what works in screening for chronic hepatitis B/C has now been translated into practical and relevant tools, including videos and animations, to enable others to replicate successful screening programmes among at risk populations in their area.
15 December 2014 | Medical Xpress
The aim of this document is to reinforce the need for urgent leadership from the Department of Health, PHE and NHS England and concerted action from Local Authorities, Health and Wellbeing Boards, Clinical Commissioning Groups (CCGs) and service providers to improve hepatitis C testing and treatment services in London for people with a history of using drugs – the group most affected by chronic hepatitis C – in order to find and treat significantly more people affected by the disease.
17 November 2014 | London Joint Working Group on Substance Use and Hepatitis C
Dr Vivian Hope of Public Health England said: "With around half of those people living with hepatitis C still unaware of their infection, we need to do more to increase diagnosis rates. Ultimately, this will help reduce the current high level of infection we’re still seeing among people who inject drugs."
05 November 2014 | Public Health England press release
While screening the blood samples of patients for HCV antibodies can be useful, a new study suggests that in some cases such antibodies may not appear for several months after HCV infection has occurred. In such cases, acute HCV infection might be missed if antibody tests alone are used for screening - RNA testing should be used to screen HCV infection.
17 September 2014 | CATIE